Scales to measure parkinsonism

Handbook of Clinical Neurology

Volumn 83, Issue , 2007, Pages

  Martínez Martín, Pablo ^a   Cubo, Esther ^a  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649341204     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)83012-0     Document Type: Review

References (164)

1. Alba A., Trainor F.S., Ritter W., et al. A clinical disability rating for Parkinson patients. J Chronic Dis 21 (1968) 507-522
2. Altman D.G. Practical Statistics for Medical Research (1991), Chapman & Hall/CRC, Boca Raton, FL
3. Andén N.E., Carlsson A., Kerstell J., et al. Oral L-dopa treatment of parkinsonism. Acta Med Scand 187 (1970) 247-255
4. Anonimous J. Appendix: available dyskinesias clinical rating scales. Mov Disord 14 (1999) 77
5. Badía X., Salamero M., and Alonso J. La medida de la salud. 2nd edn. (1999), Edimac, Barcelona 227-233
6. Bennett D.A., Shannon K.M., Beckett L.A., et al. Metric properties of nurses' ratings of parkinsonian signs with a modified UPDRS. Neurology 49 (1997) 1580-1587
7. Bergner M., Bobbitt R.A., Pollard W.E., et al. The Sickness Impact Profile: validation of a health status measure. Med Care 14 (1976) 57-67
8. Berzon R., Hays R.D., and Shumaker S.A. International use, application and performance of health-related quality of life instruments. Qual Life Res 2 (1993) 367-368
9. Birkmayer W., and Neumayer E. Die moderne medikamentose behandlung des parkinsonismus. Z Neurol 202 (1972) 257-264
10. Bowling A. Research Methods in Health. Investigating Health and Health Services. 2nd ed. (2002), Open University Press, Berkshire 289-294
11. Brod M., Mendelsohn G.A., and Roberts B. Patients' experiences of Parkinson's disease. J Gerontol B Psychol Sci Soc Sci 53 (1998) P213-P222
12. Bushnell D.M., and Martin M.L. Quality of life and Parkinson's disease: translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res 8 (1999) 345-350
13. Calne S., Schulzer M., Mak E., et al. Validating a quality of life rating scale for ideopathic parkinsonism: Parkinson's Impact Scale (PIMS). Parkinsonism Relat Disord 2 (1996) 55-61
14. Camicioli R., Grossmann S.J., Spencer P.S., et al. Discriminating mild parkinsonism: methods for epidemiological research. Mov Disord 16 (2001) 33-40
15. Canter C.J., de la Torre R., and Mier M. A method of evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 133 (1961) 143-147
16. Chaudhuri K.R., Pal S., DiMarco A., et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 73 (2002) 629-635
17. Cotzias G.C., Papavasiliou P.S., Fehlin C., et al. Similarities between neurologic effects of L-dopa and apomorphine. N Engl J Med 282 (1970) 31-33
18. Cronbach L.J. Coefficient alpha and the internal structure of tests. Psychometrika 16 (1951) 297-334
19. Cubo E., Stebbins G.T., Golbe L.I., et al. Application of the Unified Parkinson's Disease Rating Scale in progressive supranuclear palsy: factor analysis of the motor scale. Mov Disord 15 (2000) 276-279
20. de Boer A., Wijker W., Speelman J.D., et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 61 (1996) 70-74
21. Defer G.L., Widner H., Marie R.M., et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 14 (1999) 572-584
22. de Vet H.C.W., Terwee C.B., and Bouter L.M. Current challenges in clinimetrics. J Clin Epidemiol 56 (2003) 1137-1141
23. Dubois B., and Pillon B. Dementia in Parkinson's disease. In: Wolters E.C., Scheltens P., and Berendse H.W. (Eds). Mental Dysfunction in Parkinson's Disease II (1999), Academic Pharmaceutical Productions, Utrecht 165-176
24. Eidelberg D., Moeller J.R., Ishikawa T., et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 36 (1995) 378-383
25. Ellgring H., Seiler S., Perleth B., et al. Psychosocial aspects of Parkinson's disease. Neurology 43 Suppl (1993) 41-44
26. EuroQol Group. EuroQol-a new facility for the measurement of health related quality of life. Health Policy 16 (1990) 199-208
27. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism. Neurology 24 (1974) 431-441
28. Fahn S., Elton R.L.,, and Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S., Marsden C.D., Calne D.B., and Goldstein M. (Eds). Recent Developments in Parkinson's Disease Vol. 2 (1987), Macmillan Health Care Information, Florham Park, NJ 153-164
29. Fava G.A., Ruini C., and Rafanelli C. Psychometric theory is an obstacle to the progress of clinical research. Psychother Psychosom 73 (2004) 145-148
30. Fayers P.M., and Machin D. Quality of Life: Assessment, Analysis and Interpretation (2000), John Wiley & Sons Ltd., Chichester
31. Fayers P.M., and Hand D.J. Causal variables, indicator variables and measurement scales: an example from quality of life. J R Stat Soc 165 (2002) 233-261
32. Feeny D., Furlong W., Boyle M., et al. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 7 (1995) 490-502
33. Feinstein A.R. The Jones criteria and the challenge of clinimetrics. Circulation 66 (1982) 1-5
34. Feinstein A.R. Clinimetrics (1987), Yale University Press, New Haven
35. Fitzpatrick R., and Alonso J. Quality of life in health care: concepts and components. In: Martinez-Martin P., and Koller W.C. (Eds). Quality of Life in Parkinson's Disease (1999), Masson SA, Barcelona 1-15
36. Fitzpatrick R., Peto V., Jenkinson C., et al. Health-related quality of life in Parkinson's disease: a study of outpatient clinical attenders. Mov Disord 12 (1997) 916-922
37. Fitzpatrick R., Davey C., Buxton M.J., et al. Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess 2 14 (1998) 7-8
38. Fitzpatrick R., Norquist J.M., and Jenkinson C. Distribution-based criteria for change in health-related quality of life in Parkinson's disease. J Clin Epidemiol 57 (2004) 40-44
39. Fitzsimmons B., and Bunting L.K. Parkinson's disease. Quality of life issues. Nurs Clin North Am 28 (1993) 807-818
40. Friedberg G., Zoldan J., Weizman A., et al. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol 21 (1998) 280-284
41. Geminiani G., Cesana B.M., Tamma F., et al. Interobserver reliability between neurologists in training of Parkinson's disease rating scales. Mov Disord 6 (1991) 330-335
42. Giladi N., Shabtai H., Simon E.S., et al. Construction of freezing of gait questionnaire for patients with parkinsonism. Parkinsonism Relat Disord 6 (2000) 165-170
43. Ginanneschi A., Degl'Innocenti F., Maurello M.T., et al. Evaluation of Parkinson's disease: reliability of three rating scales. Neuroepidemiology 7 (1988) 38-41
44. Ginanneschi A., Degl'Innocenti F., Maurello M.T., et al. Evaluation of Parkinson's disease: a new approach to disability. Neuroepidemiology 10 (1991) 282-287
45. Goetz C.G., and Stebbins G.T. Assuring interrater reliability for the UPDRS motor section: utility of the UPDRS teaching tape. Mov Disord 19 (2004) 1453-1456
46. Goetz C.G., Stebbins G.T., Shale H.M., et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 9 (1994) 390-394
47. Goetz C.G., Stebbins G.T., Chmura T.A., et al. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord 10 (1995) 263-266
48. Goetz C.G., LeWitt P.A., and Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 18 (2003) 1455-1458
49. Goetz C.G., Poewe W., Rascol O., et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19 (2004) 1020-1028
50. Hagell P., and Widner H. Clinical rating of dyskinesias in Parkinson's disease: utility and reliability of a new rating scale. Mov Disord 14 (1999) 448-455
51. Hagell P., Whalley D., McKenna S.P., et al. Health status measurement in Parkinson's disease: validity of the PDQ-39 and Nottingham Health Profile. Mov Disord 18 (2003) 773-783
52. Hariz G.M., Lindberg M., Hariz M.I., et al. Does the ADL part of the Unified Parkinson's Disease Rating Scale measure ADL? An evaluation in patients after pallidotomy and thalamic deep brain stimulation. Mov Disord 18 (2002) 373-381
53. Hely M., Wilson A., Williamson P., et al. Reliability of the Columbia scale for assessing signs of Parkinson's disease. Mov Disord 8 (1993) 466-472
54. Henderson L., Kennard C., Crawford T.J., et al. Scales for rating motor impairments in Parkinson's disease: studies of reliability and convergent validity. J Neurol Neurosurg Psychiatry 54 (1991) 18-24
55. Heyen P. The principles of biomedical statistics. In: Masur H. (Ed). Scales and Scores in Neurology. Quantification of Neurological Deficits in Research and Practice (2004), Thieme, Stuttgart 13-51
56. Hobson P., Holden A., and Meara J. Measuring the impact of Parkinson's disease with the Parkinson's disease quality of life questionnaire. Age Aging 28 (1999) 341-346
57. Hobson J.P., Edwards N.I., and Meara R.J. The Parkinson's Disease Activities of Daily Living Scale: a new simple and brief subjective measure of disability in Parkinson's disease. Clin Rehabil 15 (2001) 241-246
58. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 17 (1967) 427-442
59. Hunt S.M., McKenna S.P., McEwen J., et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc Sci Med 15A (1981) 221-229
60. Jenkinson C., Peto V., Fitzpatrick R., et al. Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the Short-form Health Survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 24 (1995) 505-509
61. Jenkinson C., Fitzpatrick R., Peto V., et al. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 26 (1997) 353-357
62. Jenkinson C., Fitzpatrick R., Peto V., et al. The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 12 (1997) 805-814
63. Jenkinson C., Fitzpatrick R., Norquist J., et al. Cross-cultural evaluation of the Parkinson's disease questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain. J Clin Epidemiol 56 (2003) 843-847
64. Juniper E.F., Guyatt G.H., and Jaeschke R. How to develop and validate a new health-related quality of life instrument. In: Spilker B. (Ed). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. (1996), Lippincot-Raven Publishers, Philadelphia 49-56
65. Kaplan R.M. Health status: types of validity and the index of well-being. Health Serv Res 4 (1976) 478-507
66. Kartzinel R., and Calne D.B. Studies with bromocriptine. Part I. "On-off" phenomena. Neurology 26 (1976) 508-510
67. Kirshner B., and Guyatt G. A methodological framework for assessing health indices. J Chronic Dis 38 (1985) 27-36
68. Klawans H.L., and Garvin J.S. Treatment of parkinsonism with L-dopa. Dis Nerv Syst 30 (1969) 737-746
69. Korten J.J. Correlations in 80 patients with Parkinson's disease. In: Lakke J.P.W.F., Korf J., and Wesseling H. (Eds). Parkinson's Disease: Concepts and Prospects (1977), Excerpta Medica, Amsterdam 101-110
70. Kuehler A., Henrich G., Schroeder U., et al. A novel quality of life instrument for deep brain stimulation in movement disorders. J Neurol Neurosurg Psychiatry 74 (2003) 1023-1030
71. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
72. Lang A., and Fahn S. Assessment of Parkinson's disease. In: Munsat T.L. (Ed). Quantification of Neurologic Deficit (1989), Butterworths, Boston 285-301
73. Langston J.W., Widner H., Goetz C.G., et al. Core assessment program for intracerebral transplantations (CAPIT). In: Lindvall O., Bjorklund A., and Widner H. (Eds). Intracerebral Transplantation in Movement Disorders (1991), Elsevier, Amsterdam 227-241
74. Langston J.W., Widner H., Goetz C.G., et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7 (1992) 2-13
75. LaRocca N. Statistical and methodologic considerations in scale construction. In: Munsat T.L. (Ed). Quantification of Neurologic Deficit (1989), Butterworths, Boston 49-67
76. Larsen T.A., Calne S., and Calne D.B. Assessment of Parkinson's disease. Clin Neuropharmacol 7 (1984) 165-169
77. Leplège A., and Hunt S. The problem of quality of life in medicine. JAMA 278 (1997) 47-50
78. Lhermitte F., Agid Y., and Signoret L.J. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 35 (1978) 261-263
79. Lieberman A.N. Parkinson's disease: a clinical review. Am J Med Sci 267 (1974) 66-80
80. Lieberman A., Dziatolowski M., Gopinathan G., et al. Evaluation of Parkinson's disease. In: Goldstein M., Calne D.B., Lieberman A., and Thorner M.D. (Eds). Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects (1980), Raven Press, New York 277-286
81. Louis E.D., Lynch T., Marder K., et al. Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Mov Disord 11 (1996) 185-192
82. Mahieux F., Fenelon G., Flahault A., et al. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 64 (1998) 178-183
83. Marinus J., Ramaker C., van Hilten J.J., et al. Health-related quality of life in Parkinson's disease: a systematic review of disease-specific instruments. J Neurol Neurosurg Psychiatry 72 (2002) 241-248
84. Marinus J., Visser M., Martínez-Martin P., et al. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 56 (2003) 61-67
85. Marinus J., Visser M., van Hilten J.J., et al. Development of a questionnaire for sleep and sleepiness in Parkinson's disease. Sleep 26 (2003) 1049-1054
86. Marinus J., Visser M., Verwey N.A., et al. Assessment of cognition in Parkinson's disease. Neurology 61 (2003) 1222-1228
87. Marinus J., Visser M., Stiggelbout A.M., et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 75 (2004) 388-395
88. Martignoni E., Franchignoni F., Pasetti C., et al. Psychometric properties of the Unified Parkinson's Disease Rating Scale and of the Short Parkinson's Evaluation Scale. Neurol Sci 24 (2003) 190-191
89. Martinez-Martin P. Parámetros evolutivos en la enfermedad de Parkinson (1988), Universidad Complutense, Madrid (Doctoral thesis)
90. Martinez-Martin P. Rating scales in Parkinson's disease. In: Jankovic J., and Tolosa E. (Eds). Parkinson's Disease and Movement Disorders. 2nd ed. (1993), Williams and Wilkins, Baltimore 281-292
91. Martínez-Martín P. An introduction to the concept of "quality of life in Parkinson's disease". J Neurol 245 Suppl 1 (1998) 2-5
92. Martinez-Martin P. Health-related quality of life in Parkinson's disease: outcomes of the therapeutic interventions. Exp Rev Pharmacoecon Outcomes Res 1 (2001) 99-108
93. Martínez-Martín P. Calidad de vida relacionada con la salud en la Enfermedad de Parkinson (2002), Medicina stm Editores SL, Barcelona
94. Martínez-Martín P., Carrasco de la Peña J.L., Ramo C., et al. Estudio sobre la fiabilidad interobservador de escalas cualitativas en Enfermedad de Parkinson (I). Arch Neurobiol 50 (1987) 309-314
95. Martinez-Martin P., Gil-Nagel A., Morlán Gracia L., et al. Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord 9 (1994) 76-83
96. Martinez-Martin P., Gil-Nagel A., Morlán Gracia L., et al. The Cooperative Multicentric Group. Intermediate scale for assessment of Parkinson's disease. Characteristics and structure. Parkinsonism Relat Disord 1 (1995) 97-102
97. Martinez-Martin P., García Urra D., del Ser Quijano T., et al. A new clinical tool for gait evaluation in Parkinson's disease. Clin Neuropharmacol 20 (1997) 183-194
98. Martínez-Martín P., and Frades Payo B. The Grupo Centro for Study of Movement Disorders. Quality of life in Parkinson's disease: validation study of the PDQ-39 Spanish version. J Neurol 245 Suppl 1 (1998) 34-38
99. Martínez-Martín P., Gimenez Roldán S., Mateo González D., et al. Escalas de valoración de los trastornos del movimiento. In: Jiménez-Jiménez F.J., Luquin M.R., and Molina J.A. (Eds). Tratado de los trastornos del movimiento (1998), IM&C, Madrid 177-219
100. Martínez-Martín P., Frades Payo B., Jiménez Jiménez F.J., et al. The PDQ-39 Spanish Version: reliability and correlation with the short-form health survey (SF-36). Neurología 14 (1999) 159-163
101. Martinez-Martin P., Fontan C., Frades Payo B., et al. Parkinson's disease: quantification of disability based on the Unfied Parkinson's Disease Rating Scale. Neurologia 15 (2000) 382-387
102. Martinez-Martin P., Benito-León J., Alonso F., et al. Patients', doctors' and caregivers' assessment of disability using the UPDRS-ADL Section: are these ratings interchangeable?. Mov Disord 18 (2003) 985-992
103. Martinez-Martin P., Salvador C., Menendez-Guisasola L., et al. Parkinson's Disease Sleep Scale: validation study of a Spanish version. Mov Disord 19 (2004) 1226-1232
104. Martínez-Martín P., Serrano-Dueñas M., and Vaca-Baquero V. Psychometric characteristics of the Parkinson's Disease Questionnaire (PDQ-39)-Ecuadorian version. Parkinsonism Relat Disord 11 (2005) 297-304
105. Marx G.R., Bombardier E., Hogg-Johnson S., et al. Clinimetrics and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 52 (1999) 105-111
106. Masur H. Detection and evaluation of clinical deficits. In: Masur H. (Ed). Scales and Scores in Neurology. Quantification of Neurological Deficits in Research and Practice (2004), Thieme, Stuttgart 5-12
107. McDowell F., Lee J.E., Swift T., et al. Treatment of Parkinson's syndrome with L-dihydroxyphenylalanine (levo-dopa). Ann Intern Med 72 (1970) 29-35
108. McHorney C., and Tarlov A. Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res 4 (1995) 293-307
109. McRae C., Diem G., Vo A., et al. Schwab & England: standardization of administration. Mov Disord 15 (2000) 335-336
110. Miller M.D., Paradis C.F., Houck P.R., et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41 (1992) 237-248
111. Mitchell S.L., Harper D.W., Lau A., et al. Patterns of outcome measurements in Parkinson's disease clinical trials. Neuroepidemiology 19 (2000) 100-108
112. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's disease rating scale (UPDRS): status and recommendations. Mov Disord 18 (2003) 738-750
113. Nunnally J.C., and Bernstein I.H. Psychometric Theory (1994), McGraw-Hill, New York
114. Obeso J.A., Grandas F., Vaamonde J., et al. Motor complications associated with chronic L-dopa therapy in Parkinson's disease. Neurology 39 (1989) S11-S19
115. Parkes J.D., Zilkha K.J., Calver D.M., et al. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1 (1970) 259-262
116. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA 284 (2000) 1931-1938
117. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson's disease. Arch Neurol 58 (2001) 1660-1668
118. Peto V., Jenkinson C., Fitzpatrick R., et al. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 4 (1995) 241-248
119. Peto V., Jenkinson C., and Fitzpatrick R. Determining minimally important differences for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 30 (2001) 299-302
120. Petrinovich L., and Hardyck C. Behavioral changes in Parkinson patients following surgery. J Chronic Dis 17 (1964) 225 223
121. Prochazka A., Bennett D.J., Stephens M.J., et al. Measurement of rigidity in Parkinson's disease. Mov Disord 12 (1997) 24-32
122. Rabey J.M., Baas H., Bonuccelli U., et al. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 20 (1997) 322-337
123. Rabey J.M., Klein C., Molochnikov A., et al. Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading. Clin Neuropharmacol 25 (2002) 83-88
124. Ramaker C., Marinus J., Stiggelbout A.M., et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 17 (2002) 867-876
125. Reichmann H., Brecht M.H., Köster J., et al. Pramipexole in routine clinical practice. CNS Drugs 17 (2003) 965-973
126. Richards M., Marder K., Cote L., et al. Interrater reliability of the Unified Parkinson's disease rating scale motor examination. Mov Disord 9 (1994) 89-91
127. Samsa G., Edelman D., Rothman M.L., et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15 (1999) 141-155
128. Schipper H., Clinch J.J., and Olweny C.L.M. Quality of life studies: definitions and conceptual issues. In: Spilker B. (Ed). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. (1996), Lippincot-Raven Publishers, Philadelphia 11-23
129. Schrag A., Selai C., Jahanshahi M., et al. The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 69 (2000) 67-73
130. Schwab R.S. Progression and prognosis in Parkinson's disease. J Nerv Ment Dis 130 (1960) 556-566
131. Schwab R.S., and England A.C. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham F.J., and Donaldson I. (Eds). Third Symposium on Parkinson's Disease (1969), E and S Livingstone, Edinburgh 152-157
132. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life-instruments: attributes and review criteria. Qual Life Res 11 (2002) 193-205
133. Serrano-Dueñas M., Martinez-Martin P., and Vaca-Baquero V. Validation and cross-cultural adjustment of PDQL-questionnaire, Spanish versión (Ecuador) (PDQL-EV). Parkinsonism Relat Disord 10 (2004) 433-437
134. Schulzer M., Mak E., and Calne S. The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease. Parkinsonism Relat Disord 9 (2003) 291-294
135. Siderowf A., McDermott M., Kieburtz K., et al. Parkinson Study Group. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord 17 (2002) 758-763
136. Spliethoff-Kamminga N., Zwinderman A.H., Springer M.P., et al. Psychosocial problems in Parkinson's disease: evaluation of a disease-specific questionnaire. Mov Disord 18 (2003) 503-509
137. 123I-β-CIT-SPECT. J Neural Transm 107 (2000) 543-552
138. Stebbins G.T., and Goetz C.G. Factor structure of the Unified Parkinson's Disease Rating Scale: motor examination section. Mov Disord 13 (1998) 633-636
139. Stebbins G.T., Goetz C.G., Lang A.E., et al. Factor analysis of the motor section of the Unified Parkinson's Disease Rating scale during the off-state. Mov Disord 14 (1999) 585-589
140. Stevens S.S. On the theory of the scales and measurement. Science 103 (1946) 677-680
141. Streiner D.L. Clinimetrics vs. psychometrics: an unnecessary distinction. J Clin Epidemiol 56 (2003) 1142-1145
142. Streiner D.L., and Norman G.R. Health Measurement Scales: A Practical Guide to Their Development and Use. 3rd ed. (2003), Oxford University Press, Oxford
143. Thomas M., Jankovic J., Suteerawattananon M., et al. Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci 217 (2004) 89-99
144. Tison F. Intérêt et limites des échelles d'évaluation dans la maladie de Parkinson. Rev Neurol (Paris) 156 S2b (2000) 76-80
145. Trouillas P., Takayanagi T., Hallett M., et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 145 (1997) 205-211
146. van den Berg M. Leben mit Parkinson-Entwicklung und psychometrische Testung des Fragenbogens PLQ. Neurol Rehabil 4 (1998) 221-226
147. van Hilten J.J., Van der Zwan A.D., Zwinderman A.H., et al. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's disease rating scale. Mov Disord 9 (1994) 84-88
148. Visser M., Marinus J., Stiggelbout A.M., et al. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 19 (2004) 1306-1312
149. Visser M., Marinus J., van Hilten J.J., et al. Assessing comorbidity in patients with Parkinson's disease. Mov Disord 19 (2004) 824-828
150. Walker J.E., Albers J.W., Tourtellotte W.W., et al. A qualitative and quantitative evaluation of amantadine in the treatment of Parkinson's disease. J Chronic Dis 25 (1972) 149-182
151. Ware J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
152. Ware J.E., and Gandek B. IQOLA Project Group. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA project approach. J Clin Epidemiol 51 (1998) 945-952
153. Waxman M.J., Durfee D., More M., et al. Nutritional aspects and swallowing function of patients with Parkinson's disease. Nutr Clin Pract 5 (1990) 196-199
154. Webster D.D. Critical analysis of the disability in Parkinson's disease. Modern Treat 5 (1968) 257-282
155. Welsh M., McDermott M., Holloway R., et al. Development and testing of the Parkinson's disease quality of life scale: the PDQUALIF [abstract]. Mov Disord 12 (1997) 836
156. Welsh M., McDermott M.P., Holloway R.G., et al. Parkinson Study Group. Development and testing of the Parkinson's disease quality of life scale. Mov Disord 18 (2003) 637-645
157. Wenning G.K., Tison F., Seppi K., et al. Multiple System Atrophy Study Group. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 19 (2004) 1391-1402
158. World Health Organization. Handbook of Basic Documents. 5th ed. (1952), World Health Organization, Geneva 3-20
159. World Health Organization. International Classification of Impairments, Disabilities, and Handicaps: A Manual of Classification Relating to the Consequences of Disease (1980), World Health Organization, Geneva
160. World Health Organization. International Classification of Functioning, Disability and Health (2001), World Health Organization, Geneva
161. Wright J.G., and Feinstein A.R. A comparative contrast of clinimetric and psychometric methods for constructing indexes and rating scales. J Clin Epidemiol 45 (1992) 1201-1218
162. Yahr M.D., Duvoisin R.C., Schear M.J., et al. Treatment of parkinsonism with levodopa. Arch Neurol 21 (1969) 343-354
163. Martinez-Martin P. Valoración del déficit e incapacidad en la enfermedad de Parkinson. In: Obeso J.A., Tolosa E., and Grandas F. (Eds). Tratado sobre la enfermedad de Parkinson. 2nd ed. (2000), Doyma SA, Barcelona 303-310
164. Martínez-Martín P., Cubo E., and Frades B. Escalas de Valoración para síndromes parkinsonianos. In: Michel F. (Ed). Enfermedad de Parkinson y Trastornos Relacionados. 2nd edn. (2006), Editorial Médica Panamericana, Buenos Aires 573-599